00:00The studies in South Africa that have led to this concern about the variant that emerged from South Africa
00:08shows that in the study of 2,000 people, the efficacy was reduced to something like 22%.
00:15So quite a disappointing result against that particular variant.
00:18Of course, that's the variant that is much more prevalent in South Africa.
00:22If you look at the variant that's dominant in the UK, the South African variant is quite negligible at the
00:28moment.
Comments